Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $48.86 -0.27%
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Morgan Stanley analyst David Risinger downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight with a price target of $62.00 (from $70.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $62.89 yesterday.
You May Also Be Interested In
- Jefferies Downgrades LTIMindtree Ltd (LTIM:IN) to Underperform
- AU Small Finance Bank Ltd (AUBANK:IN) PT Raised to INR650 at Kotak
- Jefferies Downgrades Calix (CALX) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
